10 unknown, 8 recruiting, 2 not yet recruiting, 2 terminated. 18 Phase 1, 9 Phase 2, 2 Not applicable, 1 Early Phase 1.
Follow CAR-T cells: new trials by email Literature Review of CAR-T cells trials Research Report on CAR-T cells
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma CAR-T cells - Multiple Myeloma, Plasmacytoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 20 | 2026-12-31 | 2026-08-27 |
| A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma CAR-T cells, BCMA bispecific - Myeloma Multiple | Phase 1 / Phase 2 | Not yet recruiting | Centre Hospitalier Universitaire de Saint Etienne | 44 | 2026-12-01 | 2026-10-09 |
| Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL CAR-T cells, Venetoclax - Philadelphia Chromosome Negative ALL, Acute Lymphoblastic Leukemia, Adult | Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 77 | 2024-06-10 | 2026-03-02 |
| Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL CAR-T cells, Venetoclax, Olverembatinib - Philadelphia Positive Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult | Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 82 | 2024-06-04 | 2026-03-02 |
| Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP) CAR-T cells - ITP - Immune Thrombocytopenia | Phase 1 / Phase 2 | Recruiting | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 10 | 2024-02-01 | 2024-07-22 |
| Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine - Platinum-Resistant Ovarian Carcinoma | Phase 1 | Recruiting | City of Hope Medical Center | 33 | 2023-05-01 | 2026-08-17 |
| Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers CAR-T cells - Pancreas Cancer, CAR-T Cell Therapy | Phase 1 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 30 | 2023-03-10 | 2024-06-25 |
| Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma CAR-T cells - Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 1 | Unknown | Chongqing Precision Biotech Co., Ltd | 54 | 2021-09-06 | 2024-01-05 |
| To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL) CAR-T cells - Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma | Phase 2 | Recruiting | National University of Malaysia | 20 | 2021-06-03 | 2024-11-21 |
| Third-Generation CAR-T-cell Therapy in Individuals With HIV-1 Infection CAR-T cells - HIV-1 | Phase 1 | Unknown | Beijing 302 Hospital | 8 | 2021-05-01 | 2021-04-28 |
| Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions CAR-T cells - Hematological Malignancies | Phase 1 / Phase 2 | Unknown | Zhejiang University | 50 | 2021-03-01 | 2021-03-10 |
| Donor-derived CAR-T Cells in the Treatment of AML Patients CAR-T cells - AML | Phase 1 | Unknown | Beijing Immunochina Medical Science & Technology Co., Ltd. | 9 | 2021-03-01 | 2021-02-23 |
| A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies CAR-T cells, Ommaya Reservoir - Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma | Early Phase 1 | Recruiting | Zhejiang University | 72 | 2020-11-01 | 2020-10-26 |
| CAR-T Cellular Therapy for B Cell Malignancies Involved in CNS CAR-T cells - Hematological Malignancy | Unknown | Zhejiang University | 20 | 2020-02-28 | 2020-02-27 | |
| Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma MLM-CAR44.1 T-cells at day 0 Single intravenous infusion - Acute Myeloid Leukemia, Multiple Myeloma | Phase 1 / Phase 2 | Terminated | AGC Biologics S.p.A. | 8 | 2019-08-27 | 2022-01-19 |
| Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies CAR-T cells - Refractory, Relapsed | Phase 1 | Unknown | Henan Cancer Hospital | 20 | 2019-02-27 | 2019-03-21 |
| AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma Cyclophosphamide, Fludarabine, CAR-T Cells - Non-Hodgkin Lymphoma | Phase 1 | Active not recruiting | Benjamin Tomlinson | 31 | 2018-07-09 | 2026-02-27 |
| Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma Descartes-08, Fludarabine, Cyclophosphamide - Multiple Myeloma | Phase 1 | Terminated | Cartesian Therapeutics | 32 | 2018-03-08 | 2024-07-01 |
| Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC CAR-T Cells, CAR-T combining PD-1 Knockout, PD-1 knockout - Lung Neoplasm Malignant, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | The First Affiliated Hospital of Guangdong Pharmaceutical University | 60 | 2018-02-01 | 2018-05-16 |
| The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune Function CAR-T cells - HIV/AIDS | Phase 1 | Recruiting | Guangzhou 8th People's Hospital | 40 | 2017-10-04 | 2022-09-14 |
Showing 20 of 24. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Multiple Myeloma (4) · Recurrence (4) · Hematologic Neoplasms (3) · Lymphoma, B-Cell (3) · Lymphoma, Non-Hodgkin (3) · Acquired Immunodeficiency Syndrome (1) · Carcinoma, Non-Small-Cell Lung (1) · Leukemia, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Lung Neoplasms (1) · Nasopharyngeal Carcinoma (1) · Nasopharyngeal Neoplasms (1) · Neoplasms (1) · Pancreatic Neoplasms (1)
Institute of Hematology & Blood Diseases Hospital, China (3) · Zhejiang University (3) · 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (1) · AGC Biologics S.p.A. (1) · Affiliated Hospital to Academy of Military Medical Sciences (1) · Beijing 302 Hospital (1) · Beijing Immunochina Medical Science & Technology Co., Ltd. (1) · Benjamin Tomlinson (1) · Cartesian Therapeutics (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Chongqing Precision Biotech Co., Ltd (1) · City of Hope Medical Center (1) · Guangzhou 8th People's Hospital (1) · Henan Cancer Hospital (1) · National University of Malaysia (1)
China (18) · United States (3) · Czechia (1) · France (1) · Italy (1) · Malaysia (1)
Jianxiang Wang, Dr (2) · Benjamin Tomlinson, MD (1) · Cai Weiping, Bachelor (1) · Fabio Ciceri, MD (1) · Fu-Sheng Wang, MD (1) · Jianfeng Bi, M.D (1) · Liangding Hu, M.D. (1) · Lorna Rodriguez (1) · Metin Kurtoglu, MD, PhD (1) · Sanbin Wang, Doctor (1) · Xiaojun Huang, MD (1) · Yongping Song, Dr. (1) · Yu Hu, M.D., Ph.D (1) · Zhenfeng Zhang, MD, PhD (1)
PMID 27535056, PMID 28039295, PMID 32868878, PMID 33554732, PMID 34375315, PMID 34893603, PMID 35799791, PMID 38321811, PMID 40115173, PMID 40195173
2018 (1), 2025 (1), P30CA033572 (1), R01CA266874 (1)